Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)

NCT04952571 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Lack of funds

Conditions

Recurrent Glioblastoma

Interventions

DRUG: Camrelizumab and Bevacizumab

Sponsor

Beijing Sanbo Brain Hospital